Geron (GERN) Free Cash Flow Growth (1y) (2011 - 2026)
Powered by 
Analysis
Geron (GERN) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 82.57% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 376.81% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 9.25% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -38.10% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 38.94% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 152.82% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 203.80% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 42.27% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 42.27% |
| Mar 31, 2026 | -31.11% |
| Dec 31, 2025 | 49.62% |
| Sep 30, 2025 | 76.97% |
| Jun 30, 2025 | 48.74% |
| Mar 31, 2025 | 23.93% |
| Dec 31, 2024 | -6.83% |
| Sep 30, 2024 | -15.50% |
| Jun 30, 2024 | -66.66% |
| Mar 31, 2024 | -41.89% |
| Dec 31, 2023 | -269.19% |
| Sep 30, 2023 | -5.04% |
| Jun 30, 2023 | -19.49% |
| Mar 31, 2023 | -7.71% |
| Dec 31, 2022 | 41.58% |
| Sep 30, 2022 | -109.75% |
| Jun 30, 2022 | -57.06% |
| Mar 31, 2022 | -13.09% |
| Dec 31, 2021 | -81.90% |
| Sep 30, 2021 | -25.87% |